Stockscreener 앱 받기
438.92
2.36%
-10.61
시간 외 거래:
438.92
전일 마감가:
$449.53
열려 있는:
$448.79
하루 거래량:
1.21M
Relative Volume:
0.89
시가총액:
$111.36B
수익:
$11.74B
순이익/손실:
$3.68B
주가수익비율:
30.93
EPS:
14.1888
순현금흐름:
$3.34B
1주 성능:
-6.55%
1개월 성능:
-3.68%
6개월 성능:
-5.45%
1년 성능:
+3.46%
1일 변동 폭
$436.69
$450.44
1주일 범위
$436.69
$475.33
52주 변동 폭
$362.50
$519.68
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Nasdaq
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% - The Motley Fool
Meritage Portfolio Management Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Manning & Napier Advisors LLC Purchases 241,242 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here's what to expect from Vertex Pharmaceuticals' next earnings report - MSN
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Nordea Investment Management AB - MarketBeat
What is Vertex Pharmaceuticals Incorporated s debt to equity ratio2025 Key Highlights & Risk Adjusted Swing Trade Ideas - bollywoodhelpline.com
Vertex Pharmaceuticals Targets Five Product Launches in Five Years Across Diverse Disease Areas - geneonline.com
JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease - Pharmaceutical Technology
Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report - Barchart.com
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate - Chartmill
Sumitomo Mitsui Trust Group Inc. Acquires 45,623 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX: Strong growth in CF, pain, and renal, with five launches in five years and $12B revenue guidance - TradingView — Track All Markets
Bernstein Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
How Is The Market Feeling About Vertex Pharmaceuticals Inc? - Benzinga
Bernstein upgrades Vertex ahead of key renal trial readouts By Investing.com - Investing.com India
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Vertex Pharma Is Quietly Exploding – Here’s What Wall Street Isn’t Telling You - AD HOC NEWS
Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4 - Insider Monkey
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - Yahoo Finance
Hardman Johnston Global Advisors LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Horizon Corp Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Citizens Financial Group Inc. RI Acquires 9,963 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor MeetingsJanuary 11, 2026 - BioSpace
Vertex Pharmaceuticals Incorporated : Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - marketscreener.com
New York State Teachers Retirement System Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Best Stocks to Invest $50,000 in Right Now - Finviz
Spire Wealth Management Sells 8,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Parnassus Investments LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sumitomo Mitsui DS Asset Management Company Ltd Has $21.54 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nisa Investment Advisors LLC Has $21.85 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Oregon Public Employees Retirement Fund Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
What dividend safety score for Vertex Pharmaceuticals Incorporated stockGlobal Markets & Weekly High Conviction Ideas - ulpravda.ru
How The Vertex Pharmaceuticals (VRTX) Story Is Shifting With New Analyst Targets And CF Outlook - Yahoo Finance
Insider Sell: Ourania Tatsis Sells 4,500 Shares of Vertex Pharma - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Ourania Tatsis Sells 4,500 Shares - MarketBeat
Vertex Pharmaceuticals Officer Sells 4,500 Shares - TradingView — Track All Markets
Does Vertex Pharmaceuticals (VRTX) Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Wolfe Research Upgrade And Growing Pipeline Optimism - Yahoo Finance
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 - Finviz
State of Alaska Department of Revenue Has $14.04 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Joseph Group Capital Management Acquires 2,608 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock: Quiet chart, loud pipeline as Wall Street leans bullish - AD HOC NEWS
SG Americas Securities LLC Has $23.52 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know - MSN
Duncker Streett & Co. Inc. Has $922,000 Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex responds to NHS England's counter-offer on access to cystic fibrosis drugs - The Pharma Letter
Wagner, Vertex Pharmaceuticals evp, sells $4.39m in VRTX stock By Investing.com - Investing.com Australia
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
1.74%
자본화:
|
볼륨(24시간):